By Donna Loyle, communications specialist, LIMR
Researchers are comparing two FDA-approved oral diuretic drugs, torsemide and furosemide, to determine long-term outcomes in patients who’ve been hospitalized for heart failure.
Patients are grouped into two study arms. One group receives torsemide, while the other group receives furosemide. The initial medications are given while the patients are still in the hospital. Initial and follow-up dosing is at the discretion of the Main Line Health physician. Trial participants are followed by a minimum of one year.
Eligible patients are those who have been hospitalized (≥ 24 hours) with worsening of chronic heart failure or new diagnosis of heart failure and meet one of the following criteria:
- Left ventricular ejection fraction ≤40% within 24 months prior to and including index hospitalization
- Elevated natriuretic peptide level (either NT-pro-B-type natriuretic peptide or B-type- natriuretic peptide) during index hospitalization
The Main Line Health principal investigator for the TRANSFORM-HF cardiac clinical trial is John Clark, DO. For more information, visit https://www.mainlinehealth.org/research/clinical-trials/transform-hf